Trial intelligence / Profile preview

BOTOX in Pediatric Neurogenic Detrusor Overactivity

2012-004877-26Phase 3Completed

Sponsor
Allergan
Start
Mar 2013
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3 trial of botulinum toxin type A in detrusor hyperreflexia (DH), sponsored by Allergan. Primary endpoint: Daytime urinary incontinence episodes. Started Mar 2013; status: completed.

02

Drugs

botulinum toxin type A
03

Conditions

detrusor hyperreflexia (DH)

Beyond the preview

Go deeper on 2012-004877-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-004877-26.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call